PR in the Philippines

Kawasaki, Japan and Pittsburgh, USA, Apr 23, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited and Carnegie Mellon University (CMU) today announced the launch of the Fujitsu-Carnegie Mellon Physical AI Research Center. At the Center, Fujitsu and CMU will jointly advance research and development of core technologies to enhance the capabilities and scalability of physical AI, with the aim of serving as a global research hub that drives the social implementation of these technologies.Research focus and objectivesPhysical AI is expected to contribute to addressing key societal challenges—such as improving productivity, mitigating labor shortages, and ensuring safety—by enabling AI systems to operate in the real world and interact with people and their environments, thereby driving the automation and optimization of operations across sectors including manufacturing, logistics, construction, infrastructure, and healthcare.However, realizing this vision requires the integration of expertise and technologies across multiple domains, including robotics, AI, simulation, human–robot interaction, and ethics and social acceptance. This makes not only advancements in individual fields essential, but also interdisciplinary collaboration and efforts that bridge academic research with real-world deployment.Fujitsu and CMU established the Fujitsu-Carnegie Mellon Physical AI Research Center to address these challenges through an integrated research approach that brings together interdisciplinary expertise and connects academia and industry .A multidisciplinary collaborationAt the Center, reflecting the interdisciplinary nature of physical AI, faculty members from CMU across a wide range of disciplines—including robotics, machine learning, language technologies, human–computer interaction, electrical and computer engineering, civil and environmental engineering, and philosophy—participate in the joint research. Researchers will work alongside Fujitsu scientists, engineers, and technicians to develop physical AI systems designed to tackle real-world challenges. This close collaboration with industry informs and inspires new research directions to meet critical demand.Participating researchers include:Yonatan Bisk, Assistant Professor, Language TechnologiesFernando De La Torre, Research Professor, RoboticsTim Dettmers, Assistant Professor, Machine LearningLaszlo Jeni, Assistant Research Professor, RoboticsKris Kitani, Associate Research Professor, RoboticsDavid Lindlbauer, Assistant Professor, Human-Computer InteractionYorie Nakahira, Assistant Professor, Electrical and Computer EngineeringGraham Neubig, Associate Professor, Language TechnologiesJean Oh, Associate Research Professor, RoboticsSean Qian, Professor, Civil and Environmental EngineeringSebastian Scherer, Associate Research Professor, RoboticsPeter Spirtes, Department Head and Professor, PhilosophyKun Zhang, Professor, PhilosophyFujitsu and CMU will advance research and development through an interdisciplinary approach that integrates their respective expertise, focusing on areas such as action generation and learning, spatial perception and environmental understanding, multi-robot coordination and optimization, human-robot collaboration and the integration of simulation and real-world environments.The Fujitsu-Carnegie Mellon Physical AI Research Center will leverage CMU’s new Robotics Innovation Center, which opened in February of this year. The 14,000-square-meter facility at Hazelwood Green in Pittsburgh bridges Carnegie Mellon’s fundamental research and commercial deployment. The Robotics Innovation Center will provide specialized facilities and collaborative space to test physical AI in real-world environments.Fujitsu Kozuchi Physical OSFujitsu aims to realize a physical AI platform that can be applied to mission-critical domains supporting social infrastructure, leveraging its strengths in providing integrated AI, computing, and networking capabilities.By delivering a unified infrastructure from cloud to edge, Fujitsu seeks to ensure real-time performance, reliability, and safety, while addressing data sovereignty and governance requirements. Through these efforts, Fujitsu contributes to the development of a sustainable social foundation in which humans and robots can collaborate safely and seamlessly.As a concrete initiative, Fujitsu is developing Fujitsu Kozuchi Physical OS, which integrates robots, sensors, systems, and physical spaces (Figure 1). The platform enables the coordinated operation of multiple robots and systems in accordance with operational instructions by combining two capabilities: brain intelligence, which enhances robots’ adaptability to tasks based on prior experience and human imitation, and spatial intelligence, which provides information about real-world environments in which robots operate.Technologies developed at this research center are scheduled to be gradually incorporated into the platform starting in fiscal year 2026. This will enable the integrated utilization of physical AI technologies that combine expertise from diverse fields, enhancing adaptability to complex and dynamic real-world tasks, while also bridging interdisciplinary research outcomes to real-world deployment.Future PlansFujitsu and Carnegie Mellon University will jointly advance the research and development of core technologies for physical AI, while promoting a society in which humans and robots collaborate, and contributing to the development of a sustainable and resilient society.Executive CommentsVivek Mahajan, Corporate Executive Officer, Corporate Vice President, CTO, in charge of System Platform, Fujitsu Limited, comments:“We are delighted to announce the establishment of a joint center for physical AI with Carnegie Mellon University, a global leader in the fields of robotics and AI.At this research center, Fujitsu will create new value through the convergence of AI, computing, networking, and robotics, and accelerate the societal implementation of reliable physical AI. Furthermore, to realize a society where humans and robots coexist and collaborate, we will expand our research scope to areas that underpin the social infrastructure and contribute to the building of a sustainable society.”Martial Hebert, Dean and University Professor of Robotics, School of Computer Science, comments: “The Fujitsu-Carnegie Mellon Physical AI Research Center builds on CMU's focus on developing AI and robotics systems to tackle real-world problems and the university's collaboration with industry to put those innovations into practice and inspire what's next. Physical AI will fuel the machines of tomorrow, allowing for competent decision-making, enhanced efficiency, greater safety, and, perhaps most importantly, trust to work alongside humans in critical fields. Carnegie Mellon is excited to have Fujitsu as our partner to continue to lead in physical AI.”About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsu Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Zurich, Apr 23, 2026 - (ACN Newswire via SeaPRwire.com) - Akkodis, a global leader in digital engineering consulting and part of the Adecco Group has been named a "Leader" by Information Services Group (ISG) in the ISG Provider Lens™ Digital Engineering Services 2026 reports, recognizing the company's strength across critical engineering and technology domains in Europe and the United States.Image: Akkodis named leader in ISG Digital Engineering Services 2026. Source: AkkodisAkkodis earned Leader status in the following quadrants:Augmented Design and R&D Services (Europe)Intelligent Operations and Connected Experiences (Europe)Integrated Platform and Application Services (Europe and U.S.)Leadership in augmented design & R&D servicesISG highlights Akkodis' expertise in end‑to‑end product development, including systems architecture, Model-based Systems Engineering (MBSE) integration, unified tool chains and multi‑domain engineering. The company's digital twin methodologies support deep physical-digital integration for safety‑critical products. By integrating engineering and digital toolchains, Akkodis accelerates agile product development from concept to lifecycle management across automotive, aerospace, rail and industrial sectors.ISG also recognizes Akkodis' leadership in software-defined vehicle (SDV) engineering, with capabilities spanning hardware-in-the-loop (HIL) automation, telemetry pipelines, cloud‑scale validation and AI‑supported analytics. This has been successfully showcased through the Akkodis SDV Academy where clients accelerate advanced driver‑assistance systems (ADAS) and SDV verification while addressing engineering talent gaps. Expertise in embedded systems, sensor fusion and real‑time software reinforces Akkodis' position across mobility, industrial and defense applications.Advancing intelligent operations & connected experiencesISG recognizes Akkodis for advancing industrial intelligence and transforming factory and mission-critical operations. Through smart commissioning frameworks, digital twins and advanced simulation tools, the company helps clients accelerate digital factory planning, reduce layout risks and improve overall equipment effectiveness (OEE). Akkodis also supports predictive quality and maintenance through acoustic sensing, physics-based AI and data-driven diagnostics. Its operations capabilities (including ruggedized hardware engineering, over-the-air (OTA) lifecycle management and industrial asset health solutions), have been applied across industries and asset-intensive environments requiring reliability, safety compliance, environmental resilience and long-term continuity.Strength in Integrated Platform & Application ServicesAkkodis' digital solutions advance AI‑led autonomous engineering by accelerating validation, enhancing quality and enabling compliance‑by‑design at scale. In Europe, ISG highlights Akkodis' Unified AI Platform, powered by AI-Core, alongside its deep expertise in cloud, hybrid and sovereign architectures, including AWS, Azure and sovereign deployments, which helps organizations balance agility with security, compliance and data residency requirements.In the U.S., ISG cites Akkodis' leadership in cloud‑native, MACH‑aligned modernization. Its AI‑enabled development frameworks embed intelligence into workflows, accelerating modernization and enabling personalized digital experiences. DevSecOps, compliance‑by‑design models and a secure, modular AI‑Core platform, enable Akkodis to provide scalable, cloud‑native innovation and flexible integration across modern enterprise and platform ecosystems."We are proud to receive this recognition from ISG which underscores the depth of Akkodis' global digital engineering expertise and our ability to combine AI‑driven engineering, cloud‑agnostic platforms and compliance‑by‑design at global scale to help clients innovate with Akkodis Intelligence across dynamic and complex environments," said Jo Debecker, President & CEO of Akkodis.Shirish Madhukar Kulkarni, Lead Analyst, ISG, said, "Akkodis uniquely combines deep engineering expertise with AI‑led digital twins and scalable platforms to enable faster product innovation, resilient operations, and connected, data‑driven experiences." Srinivasan P N, Senior Lead Analyst, ISG added, "Akkodis' leadership is rooted in four decades of European engineering excellence, where systems engineering, validation depth and software defined innovation converge through Akkodis Intelligence to deliver trusted, AI enabled digital engineering at scale."Media contactsAnne FriedrichSVP, Global Head of Communications, AkkodisM. +4915174633470E. anne.friedrich@adeccogroup.comLisa BushkaVP, External Communications, AkkodisM. +18604630770E. lisa.bushka@adeccogroup.comAbout AkkodisAkkodis is a global digital engineering consulting company that enables organizations to innovate and accelerate by applying technology to redefine how processes and products are developed, powered and optimized. With deep expertise across AI, data, cloud, edge and software engineering, we offer best-in-class technology consultancy. Through our strong, scalable delivery models and specialized talent, we provide end-to-end solutions, from strategy and consulting through implementation. Our commitment to Akkodis Intelligence helps businesses connect the exponential power of technology with the irreplaceable strengths of human thinking and collaboration. Part of the Adecco Group and headquartered in Switzerland, Akkodis brings together 40,000 engineers and digital experts in over 30 countries, with services that span Consulting, Solutions and Academy. With deep experience across the world's major industries, Akkodis empowers businesses to solve complex challenges and achieve sustainable impact.  akkodis.com | LinkedIn | Instagram | Facebook | XAbout the Adecco GroupThe Adecco Group is the world's leading talent company. Our purpose is making the future work for everyone. Through our three global business units - Adecco, Akkodis and LHH - across 60 countries, we enable sustainable and lifelong employability for individuals, deliver digital and engineering solutions to power transformation and empower organisations to optimise their workforces. The Adecco Group leads by example and is committed to an inclusive culture, fostering sustainable employability, and supporting resilient economies and communities. The Adecco Group AG is headquartered in Zurich, Switzerland (ISIN: CH0012138605) and listed on the SIX Swiss Exchange (ADEN). www.adeccogroup.comAbout ISGISG (Information Services Group) is a leading global technology research and advisory firm. A trusted business partner to more than 900 clients, including more than 75 of the world's top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,600 digital-ready professionals operating in more than 20 countries-a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry's most comprehensive marketplace data. For more information, visit www.isg-one.com.SOURCE: Akkodis Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Apr 23, 2026 - (ACN Newswire via SeaPRwire.com) - Sinch Mailgun, part of Sinch, has released its Email Impact Report 2026, introducing new industry benchmarks across 10 high-volume sending sectors and revealing a gap between email performance and execution.Based on insights from more than 400 billion emails sent in 2025 and a global survey of over 1,200 email senders, the report shows that while email remains a critical, high-performing channel, poor deliverability is leaving significant revenue on the table. Nearly 18% of emails fail to reach the inbox, putting up to a fifth of potential return on investment at risk for many organisations.78% of respondents say email is critical to business success. At the same time, the research highlights a growing disconnect between performance and execution, driven by gaps in measurement, deliverability practices and AI application.“APAC businesses rely heavily on email to drive sales, loyalty and customer experience but many are not set up to capture its full value,” said Ginger Kidd, Vice President Marketing & Communications APAC at Sinch. “What we see in this data reflects what’s happening locally: brands are investing in email and seeing strong returns, yet there is still a high number of messages that never reach inboxes. For instance, in a market as competitive and cost-conscious as Australia, marketers simply can’t afford for emails to get lost in inboxes. When budgets are under pressure, fixing deliverability is one of the fastest ways to unlock more value from the spend they already have.”AI adoption is widespread, but its impact remains uneven. Many teams focus on basic use cases such as content generation, while higher-impact applications such as optimisation, segmentation and deliverability remain underutilised. Organisations that use AI more effectively are significantly more likely to report improved email performance.Ginger Kidd said: "Across the diverse markets of APAC, we’re seeing a common theme: marketers are enthusiastically adopting AI, but the initial focus has primarily been on content creation. The true opportunity now lies in leveraging AI for smarter decision-making. For instance, who to send to, how often, and with what level of risk. This strategic shift is the key to ensuring every campaign improves performance, not just adds volume.“The most sophisticated teams are already using AI to predict which subscribers are at risk of disengaging, to fine-tune send times and to protect sender reputation. That’s where we’re seeing a real uplift in performance, not just faster content production.”Key findings of the report include:60% of companies measuring email ROI report returns above $10 for every $1 spentMore than 1 in 10 achieve returns as high as 40:146% say AI improves speed and efficiency41% of teams use AI to generate email content23% say AI has not improved their email programs49% report improved email performance year-over-year79% plan to maintain or increase investment in emailFewer than half of organisations can confidently measure email ROIAbout the reportThe Email Impact Report 2026 combines:Data from 400+ billion emails sent in 2025Insights from 1,200+ email senders globallyBenchmarks across 10 high-volume industriesRead more about the report here.About SinchSinch’s vision is to connect every business with every customer, everywhere in the world. With the industry’s most trusted foundation for intelligent customer communications, Sinch powers over 900 billion customer interactions annually for more than 200,000 customers across the globe. Leading global companies, including AI innovators, rely on Sinch to strengthen customer relationships and deliver seamless experiences across messaging, email and voice. Profitable since its founding in 2008, Sinch generated net sales of USD 3 billion (SEK 27 billion) in 2025 and has over 4,000 Sinchers in 60 countries, with headquarters in Stockholm. Sinch is listed on Nasdaq Stockholm (XSTO: SINCH). Visit us at sinch.com.About Sinch MailgunSinch Mailgun is the email infrastructure platform built for developers and businesses that demand reliable, high-performance delivery at scale. Trusted by companies worldwide, Mailgun powers transactional, marketing, and programmatic email through a developer-first API, advanced deliverability tools, and real-time analytics. As part of Sinch — the industry’s most trusted foundation for intelligent customer communications — Mailgun connects businesses to their customers through every send, at every scale. Visit us at mailgun.com.For more information, please contact:Tracey ChooCommunications Manager, APAC at SinchE-mail: tracey.choo@sinch.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

PHILADELPHIA, PA, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in AI-driven data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced the issuance of U.S. Patent No. 12,596,819 and Notices of Allowance on two additional U.S. patent applications. This milestone builds directly on the Company's December 2025 issuance of two foundational patents for blockchain-driven content licensing and tokenized monetization - further expanding its robust intellectual property portfolio headlined by the industry-defining Carbon Credit Tokenization Patent.Key Highlights for InvestorsOne newly issued patent and two Notices of Allowance extend protection across three high-value platforms: AI-validated data valuation & monetization, tokenized virtual location funding, and automated tax return preparation for digital assets and DeFi-directly addressing 1099-DA compliance challenges.Reinforces the Company's Sumerian® Crypto Anchors, DataValue®, DataScore®, and Information Data Exchange® (IDE®) technologies with quantum-resistant encryption and blockchain immutability, underpinning a growing pipeline of tokenization contracts and licensing deals.Arrives as the first full IRS Form 1099-DA filing season closes amid reported operational hurdles-including late deliveries by Coinbase, Kraken, and Gemini-demonstrating clear demand for Datavault AI's automated, tokenized tax solutions.Enabled use cases include tokenized commodities (copper, gold, precious metals), agricultural/genomic/healthcare data assets, NIL digital twins, funded virtual biotech marketplaces, and intelligent tax automation-integrating natively with the Company's edge GPU fleet and HPC infrastructure.Directly supports Datavault AI's 2026 revenue target of at least $200 million, accelerates commercialization across fintech, healthcare, biotech, energy, agriculture, sports & entertainment, and Web3, and opens new licensing and partnership opportunities.Scope of the Latest ProtectionsU.S. Patent No. 12,596,819 - "Method and System for Data Valuation and Secure Commercial Monetization Platform" (issued): Covers an end-to-end permissioned platform spanning opt-in data contribution, AI-driven automated valuation, blockchain-tokenized storage in the Datavault®, and trading on open exchanges with flexible compensation pathways (sales, licenses, rewards, charitable contributions).U.S. Patent Application No. 17/842,220 - "System and Method for Funding a Virtual Location" (Notice of Allowance): Protects the funding, authentication, and tokenized operation of organization-specific virtual locations, including multi-currency donations, integrated event and asset tokenization, portfolio-aligned advertising, and compensation mechanisms for data contributors.U.S. Patent Application No. 17/507,459 - "Platform and Method for Preparing a Tax Return" (Notice of Allowance): Covers automated tax return preparation for clients and employees, with specialized tokenized return handling for digital asset and DeFi activity, back-end form processing, and dynamic adjustment to evolving tax codes-precisely targeting the reconciliation burdens and visibility gaps plaguing the inaugural 1099-DA season.Market Context & TailwindsThe filings position Datavault AI at the convergence of three rapidly expanding markets. Tokenized real-world assets have already surpassed $30 billion in on-chain value (RWA.xyz 2025 data), with Boston Consulting Group and ADDX projecting the global market to exceed $16 trillion by 2030. The global data monetization market is forecast to grow from $7.53 billion in 2024 to $18.8 billion by 2033 (10.7% CAGR, SkyQuest Technology). The new tax-preparation patent arrives precisely as U.S. taxpayers navigate the first full season under the IRS Form 1099-DA digital asset broker reporting regime-where gross proceeds reporting began January 1, 2025, and basis reporting for certain transactions took effect January 1, 2026-amid well-documented industry friction around late broker filings and cross-wallet/chain/DeFi reconciliation.Investor Implications & Strategic OutlookCollectively, the issued patents and allowed applications extend IP coverage around innovations that transform raw data into tokenized, tradable assets and enable transparent funding, monetization, and automated tax handling of virtual environments and digital asset portfolios. These technologies are expected to integrate seamlessly with Datavault AI's anticipated edge GPU fleet and high-performance computing infrastructure, accelerating AI valuation processing and tokenization contract execution."Securing this issued patent and receiving Notices of Allowance on two additional applications validates our leadership in turning intangible data into verifiable, monetizable capital, and in enabling organizations to fund and operate virtual worlds with full transparency and user compensation," said Nathaniel T. Bradley, Founder and Chief Executive Officer of Datavault AI. "These filings deepen our competitive moat and accelerate our path to capturing meaningful share in the data asset, real-world asset, and digital asset tax-preparation markets-directly fueling our $200 million 2026 revenue target and expanding pipeline of tokenization contracts."For additional insight into Datavault AI's growth strategy, commercialization roadmap, and long-term vision for unlocking value from data and intellectual property through tokenization and licensing, investors are encouraged to view the recent Nasdaq interview with CEO Nathaniel Bradley, hosted by Tech Edge and now available at https://vimeo.com/1176174810About Datavault AI Inc.Datavault AI™ (NASDAQ:DVLT) is a pioneer in AI-driven data experiences, valuation, and monetization of assets in the Web 3.0 environment. The Company's cloud-based platform delivers comprehensive solutions across its Acoustic Sciences and Data Sciences divisions. Datavault AI's Acoustic Sciences division features WiSA®, ADIO®, and Sumerian® patented technologies for spatial and multichannel wireless, high-definition sound transmission. The Data Science Division harnesses Web 3.0 and high-performance computing to enable experiential data perception, valuation, and secure monetization across industries, including sports & entertainment, biotech, education, fintech, real estate, healthcare, energy, and more. The Information Data Exchange® (IDE®) is a token exchange technology powered by Nasdaq Financial Infrastructure. The Company owns and operates exchanges, including International Elements Exchange (IEE), Sports Illustrated Exchange (SIx), New York Interactive Advertising Exchange (NYIAX), and American Political Exchange (APE). The Company is headquartered in Philadelphia, PA. Learn more at https://www.dvlt.ai.Forward-Looking Statements: This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release, including statements regarding the Company's future operations, financial position, prospects, plans, objectives, expectations, and intentions, are forward-looking statements. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this release include, but are not limited to, statements regarding: (i) the ultimate issuance, scope, validity, and enforceability of U.S. Patent Application No. 17/842,220, U.S. Patent Application No. 17/507,459, and any related foreign or continuation applications; (ii) the commercial value, market adoption, and revenue contribution of the Company's patented and patent-pending technologies, including DataValue®, DataScore®, the Information Data Exchange® (IDE®), Sumerian® Crypto Anchors, and the Datavault® platform; (iii) the Company's ability to achieve its 2026 revenue target of at least $200 million; (iv) the Company's pipeline of tokenization contracts, licensing arrangements, and strategic partnerships; (v) the size, growth, and timing of the markets for tokenized real-world assets, data monetization, and digital-asset tax preparation; (vi) the integration and performance of the Company's anticipated edge GPU fleet and high-performance computing infrastructure; and (vii) the demand for automated tax-preparation solutions arising from IRS Form 1099-DA reporting requirements.These forward-looking statements are based on management's current expectations and assumptions and are subject to significant risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such risks include, among others: the U.S. Patent and Trademark Office issuing claims narrower than those allowed or rejecting allowed claims on reexamination; delays or failures in commercializing the Company's patented and patent-pending technologies; the Company's ability to attract and retain customers, licensees, and exchange partners; competition from existing and emerging technologies; cybersecurity, blockchain protocol, and quantum-computing risks; changes in U.S. federal and state tax law affecting digital-asset reporting, including modifications to the Form 1099-DA regime; regulatory developments affecting digital assets, securities, data privacy, and tokenized real-world assets; the Company's ability to raise additional capital on acceptable terms; macroeconomic and capital-markets conditions; and the other risk factors discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings made with the U.S. Securities and Exchange Commission (the "SEC"), copies of which are available free of charge on the SEC's website at www.sec.gov.Except as required by applicable law, the Company undertakes no obligation, and expressly disclaims any duty, to update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances, or otherwise. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company gives no assurance that it will achieve its expectations. This release does not constitute an offer to sell, or the solicitation of an offer to buy, any security. Any forward-looking statements regarding potential acquisitions, dispositions, joint ventures, strategic alliances, licensing transactions, or similar arrangements are subject to the negotiation, execution, and consummation of definitive agreements and the satisfaction of customary closing conditions, and no assurance can be given that any such transaction will be completed on the terms contemplated, on the timing anticipated, or at all.Industry and Market Data: This press release contains industry, market, and competitive position data, including statistics, forecasts, and projections, that are based on or derived from independent industry publications, third-party research, surveys, and reports, including data attributed to RWA.xyz, Boston Consulting Group, ADDX, SkyQuest Technology, and the U.S. Internal Revenue Service. The Company has not independently verified the accuracy or completeness of any such third-party information and makes no representation or warranty, express or implied, as to its reliability. Industry publications and forecasts of this nature are inherently subject to assumptions, methodological limitations, and uncertainties, and projections, estimates, and beliefs based on such data may not prove to be accurate. Actual market size, growth rates, and the Company's position within these markets may differ materially from the figures presented herein.Trademarks, Trade Names, Service Marks and Copyrights: Datavault AI™, DataValue®, DataScore®, Information Data Exchange®, IDE®, Datavault®, WiSA®, ADIO®, and Sumerian® are trademarks, service marks, or registered trademarks of Datavault AI Inc. in the United States and/or other jurisdictions. This press release also refers to trademarks, service marks, trade names, and copyrights owned by other companies, including those of Coinbase, Kraken, Gemini, and Nasdaq. Solely for convenience, certain of the trademarks, service marks, trade names, and copyrights referred to in this press release may be listed without the ™, ®, ©, or SM symbols, but the Company will assert, to the fullest extent under applicable law, its rights to its own trademarks, service marks, trade names, and copyrights. The use or display of other parties' trademarks, service marks, trade names, or copyrights is not intended to and does not imply a relationship with, or endorsement or sponsorship by, the Company of any such third party.Media Contact:marketing@dvlt.aiInvestor Contact:Edward BargerVP Investor Relationsebarger@dvlt.ai | ir@dvlt.aiSOURCE: Datavault AI Inc Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - China Gas Holdings Limited (“China Gas” or the “Group”; stock code: 384), a leading city gas operator in China, announced that it has entered into a strategic cooperation agreement with CITIC Construction Co., Ltd. (“CITIC Construction”) and China CITIC Bank Corporation Limited (“China CITIC Bank”). Based on the principles of “resource sharing, complementary strengths, shared benefits and mutual success”, the three parties will establish an integrated “industry-construction-finance” ecosystem-based collaborative model. This partnership aims to further support the development of China Gas’ new businesses, including energy storage and biomass energy, and jointly deepening engagement in global energy infrastructure and green low-carbon industries.China Gas, CITIC Construction and China CITIC Bank officially sign a tripartite strategic cooperation agreementThis collaboration represents an important step by all parties in actively responding to China’s “15th Five-Year Plan” and deepply participating in the Belt and Road Initiative. According to the agreement, the three parties will establish a comprehensive strategic partnership and conduct in-depth cooperation across various areas, including overseas energy infrastructure construction, joint development of third-party projects, industrial park businesses, green finance and various financing collaborations. They have adopted a closed-loop, ecosystem-based collaborative model: China Gas serves as the business model leader, responsible for project planning, technical solutions, and operations; CITIC Construction acts as the engineering and construction executor, leveraging its strengths in local resource coordination and construction management; China CITIC Bank, as the financial services provider, will meetinvestment and financing needs.To address global climate change and energy security challenges, the three parties will focus on the core areas, including: i) Prioritizing high-potential regions including Europe, Southeast Asia, Central Asia, and North Asia to jointly promote the development and construction of energy infrastructure, ii) Integrating their resources around the industrial parks and new urbanization projects led and developed by China Gas at home and abroad, iii) Working  together to implement the “green development” strategy and engage in in-depth collaboration in the areas of investment and financing.To capitalize on the opportunities presented by the global energy transition and the national “dualcarbon” goals, the Group is accelerating the development of two new growth drivers: its new energy business centered on energy storage and its biomass energy business. In the energy storage sector, the Group is seizing the strategic opportunities created by power market reforms and the development of a new power system, while continuing to deepen its market presence and optimize its layout, with a focus on “concentrating efforts in core regions and achieving key breakthroughs in overseas markets”. Meanwhile, the Group is actively expanding its biomass business and achieving growth across multiple fronts. It has previously entered cooperation agreements with several leading enterprises, including Deyi Energy (a subsidiary of Chery Automobile) and EVE Energy, as well as local governments, to jointly advance the construction of zero-carbon industrial parks and the clean upgrading of industries. This cooperation will further support the Group in expanding its domestic and overseas markets, focusing on the two new growth engines of “energy storage + biomass energy”, and promoting the Group’s healthy and sustainable development.Mr. LIU Ming Hui, Chairman and President of China Gas, said, “After more than two decades of development, China Gas has built a comprehensive business structure centered on natural gas, integrating LNG, LPG, biomass energy, and new energy technology. We are currently accelerating our globalization strategy and have formed a clear business footprint in regions such as Europe, Southeast Asia, Central Asia, and North Asia. The signing of this tripartite agreement with CITIC Construction and China CITIC Bank marks our shift from simple overseas expansion to a cluster-based international strategy driven by industry leadership, empowered by engineering expertise, and finance support. Through close collaboration with our partners in finance and industry, we will leverage our stronger risk resilience and our industry chain advantages to contribute China Gas solutions to the sustainable development of global energy.”About China Gas Holdings LimitedChina Gas Holdings Limited ("China Gas", stock code: 384. HK) is a leading gas service provider. Focusing on China, it principally specializes in the investment, construction and operations of city gas pipeline infrastructure, distribution of natural gas and LPG to residential, industrial and commercial users, as well as construction and operations of gas refilling stations for vehicles and vessels. Currently, China Gas owns a total of 662 city and township gas projects with concession rights, 32 long-distance pipeline transmission projects of natural gas, 485 CNG and LNG refilling stations for vehicles and vessels, as well as 120 LPG distribution projects. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Kuala Lumpur, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) — CBL International Limited (NASDAQ: BANL) (“CBL” or the “Company”), a Nasdaq-listed marine fuel logistics and bunkering facilitator of Banle Group (“Banle” or “the Group”) focused on the Asia-Pacific region, today announced the acquisition of a 50.5% majority stake in Green Marine Energy Holdings Limited (“GMH”), a British Virgin Islands incorporated company. The transaction will be executed by CBL’s wholly-owned subsidiary, which has signed the Share Sale and Purchase Agreement (the “SPA”) as the buyer. To support the transaction, CBL will provide a corporate guarantee to the sellers, securing the payment obligations of its subsidiary.GMH operates two complementary businesses in Malaysia: feedstock trading for sustainable aviation fuel (SAF) and biofuels, and ship biofuel supply together with traditional bunkering services. The feedstock trading arm holds the necessary licenses to source and trade raw materials used in SAF and biofuel production, supported by an established network of suppliers and customers. Its bunkering operations include a license to supply both conventional bunker fuel and biofuels within Malaysian waters.This strategic investment aligns with growing global emphasis on environmental, social, and governance (ESG) considerations and evolving regulatory requirements in the maritime and aviation sectors. CBL’s financial resources and operational expertise in marine fuel logistics are expected to support GMH’s expansion, complementing it to scale its feedstock trading activities and explore opportunities to supply SAF-related producers in Malaysia.Malaysia is seeing increased investment in sustainable fuel infrastructure, with new commercial-scale SAF production facilities opening and planned in the country. These developments further underscore the potential for feedstock demand in the region.In the bunkering segment, GMH’s license positions the combined group to develop traditional and biofuel bunkering supply capabilities at key Malaysian ports, including Port Klang—one of the world’s top ten ports by throughput. This builds on CBL’s existing bunkering facilitation services and supports the industry’s transition toward lower-carbon marine fuels.Dr. Teck Lim Chia, Chairman and Chief Executive Officer of CBL, commented: “This acquisition represents a measured step to broaden our presence in the sustainable energy supply chain while leveraging our core strengths in marine fuel services. We look forward to working with the GMH team to support the responsible growth of these businesses in line with market developments.”The transaction is expected to enhance CBL’s long-term positioning in the evolving marine and energy sectors without altering the Company’s primary focus on its established bunkering facilitation activities.About the Banle GroupCBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistic company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in over 70 major ports covering Australia, Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Netherlands, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam, as of 17 April, 2026. The Group actively promotes the use of sustainable fuels and is awarded with the ISCC EU and ISCC Plus certifications, as well as EcoVadis Silver Medal.For more information about our company, please visit our website at: https://www.banle-intl.com.Forward-Looking StatementsCertain statements in this announcement are not historical facts but are forward-looking statements. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “could,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” “should,” “would,” “future,” “outlook,” “potential,” “project” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other performance metrics and projections of market opportunity. They involve known and unknown risks and uncertainties and are based on various assumptions, whether or not identified in this press release and on current expectations of BANL’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of BANL. Some important factors that could cause actual results to differ materially from those in any forward-looking statements could include changes in domestic and foreign business, fuel prices and tariffs, market, financial, political and legal conditions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.CBL INTERNATIONAL LIMITED(Incorporated in Cayman Islands with limited liabilities)For more information, please contact:CBL International LimitedEmail: investors@banle-ntl.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - April 22, 2026) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that Stuart Watson — former global Head of Technical Development for Rio Tinto Ltd. (ASX: RIO), one of the largest mining and mineral production companies in the world, has joined GMG as Chief Production Growth Officer.Stuart has over 30 years of global leadership experience in metals and mining and oil and chemicals, including 20 years at Rio Tinto, across operations, sales and marketing, mergers and acquisitions, and technology development and innovation. Career highlights include:Leading and delivering multiple major transformation programs valued over US$5 Billion and merger and acquisition deals valued at US$1 Billion.Directing US$1 Billion in global technology and research & development spend to create breakthrough growth options and projectsBuilding high-performing global teams across Asia, Europe, and North AmericaStuart has a Master of Business Administration (MBA) - Henley Management College, UK; is a Chartered Engineer - Institute of Chemical Engineers (IChemE), has a Masters of Engineering, Chemical Engineering (First Class Honours) — Imperial College, University of London and Ecole Nationale Supérieure d'Ingénieurs de Génie Chimique (ENSIGC), Toulouse, France.Craig Nicol, CEO & Managing Director of the Company, commented "We welcome Stuart to the GMG team - he is a great addition to the Senior Executive Team for both executive leadership and delivery capability. I will enjoy working with Stuart to expand our production across our graphene and graphene products around the world."Jack Perkowski, Non-Executive Chairman and Director of the Company, commented: "On behalf of the board I welcome Stuart to the team and look forward to the progress around expanding our production capability into North America."Operations UpdateGMG is focused on delivering its Gen 2.0 Graphene Production Project (the "Gen 2.0 Project") by end of June 2026 — which is expected to produce at least 10 tonnes per annum of graphene at its headquarters in Richlands, Queensland, Australia.Once the Gen 2.0 Project is commissioned and operating. GMG plans to replicate and establish other production plants around the world to enable scaled production for potential sales, diversify and lower production risks, and in the end, reduce operating costs by locating the plant in countries with lower operating costs, including low cost natural gas — one of GMG's key production input costs.Currently, GMG is planning three potential expansion projects — two in North America (potentially one in US and one in Canada) in addition to an expansion production project in Australia. GMG proposes to mature these projects and expand production in line with sales for all of its products.The expansion program for GMG includes the following 5 production plants:Graphene Production (from natural gas)Coating Blend Plant (for the graphene coating THERMAL-XR®)Lubricant Blend Plant (for the graphene lubricant additive G® LUBRICANT)Graphene Slurry Plant (for the SUPA G Lithium-Ion Battery Additive)Battery Assembly Plant (for the Graphene Aluminium Ion Battery)Figure 1To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/293781_d1c07d1d84356a2d_001full.jpgAbout GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed at improving the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "believes" "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements as to GMG's focus on, and the timing and production expectations of, the Gen 2 Project, intentions regarding the number, purpose and location of expansion projects, intentions to de-risk and develop commercial scale-up capabilities, GMG's focus in the energy savings segment, GMG's intentions for the use of graphene lubricant additive on saving liquid fuels, expectations for R&D and commercialization of G+AI Batteries, GMG's ability to improve the performance of lithium-ion batteries and GMG's critical business objectives.Such forward-looking statements are based on a number of assumptions of management, including the patent and potential market size of G® LUBRICANT. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation that GMG does not receive or receive on a timely basis the fully signed consent notice from the and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/293781 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

KYOTO, Japan, Apr 22, 2026 - (JCN Newswire via SeaPRwire.com) - OMRON Healthcare Co., Ltd., a global leader in clinically proven medical devices for home health monitoring and treatment, today announced the integration of its ECG-enabled upper arm blood pressure monitors with Tricog Health Pte. Ltd.’s clinically validated AI-powered cardiac triage service, Tricog CardioCheck (TCC). The service is scheduled for rollout at health centers across India from April 2026. Tricog CardioCheck (TCC) enables ECG data recorded using OMRON Healthcare’s Complete™ blood pressure monitors with integrated ECG monitoring to be transmitted to the cloud and analyzed by Tricog’s AI algorithms. Within approximately 10 seconds, the system provides a three-level risk assessment, supporting patient triage and timely clinical evaluation.Results are displayed via a dedicated smartphone application designed for healthcare professionals, allowing front-line care providers to review patient risk levels in real time and quickly determine the need for further examination, even where a cardiology specialist is not immediately available.Cardiovascular disease represents a growing public health challenge in India, with the number of patients projected to increase from approximately 110 million today to 230 million by 2050. At the same time, access to specialized care remains limited, with far fewer cardiology specialists per capita than Japan or the United States and limited access to facilities equipped for advanced cardiac testing.While early identification can be crucial to the effective management of cardiovascular conditions such as heart failure and heart attacks, helping to reduce the risk of serious complications including strokes, many cases go undetected until overt symptoms begin to develop.By integrating ECG measurement into routine blood pressure monitoring at clinics, Tricog CardioCheck (TCC) supports the identification of patients whose underlying conditions may otherwise go undiagnosed. Furthermore, the system enables cardiovascular screening to be incorporated into existing workflows without significantly increasing operational burden, facilitating earlier detection and more timely referral for further evaluation.Since its initial investment in Tricog in fiscal year 2023, OMRON Healthcare has continued to strengthen its partnership with the company in order to address key healthcare challenges in India. Through ongoing collaboration, both companies aim to expand access to innovative diagnostic solutions and contribute to improving cardiovascular health outcomes across the country.About OMRON HealthcareCommitted to advancing health and empowering people worldwide to live life to the fullest, OMRON Healthcare is a global leader in the field of clinically proven, innovative medical equipment for home health monitoring and treatment. Aiming to realize its vision, “Going for ZERO, Preventive Care for the Health of Society,” the company develops products for cardiovascular condition management, respiratory care, and pain therapy. Building on this, it has introduced a new digital health ecosystem that bridges patients and healthcare professionals, helping to reduce cerebro-cardiovascular events, the worsening of respiratory diseases, and limitations caused by chronic pain.With over 400 million units sold globally, OMRON provides the world's most recommended blood pressure monitors by healthcare professionals. Throughout its history, OMRON Healthcare has striven to improve lives and contribute to a better society by developing innovations that help people prevent, treat, and manage their medical conditions, providing products and services in over 130 countries.For more information, please visit: Website: https://healthcare.omron.com/LinkedIn: https://www.linkedin.com/company/omron-healthcare-co-ltd-/Media enquiriesThis press release is disseminated by Kyodo PR on behalf of OMRON Healthcare. For more information or for interview opportunities, please contact:OMRON Healthcare Press Desk: omronhealthcare-pr@kyodo-pr.co.jp  Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Transaction will create a global powerhouse for mining finance and reduce complexity and costs for Canadian market participantsAcquisition will strengthen TMX's ability to serve clients across the capital markets ecosystem, expands global presence, accelerates growth strategyAnalyst webcast and conference call on Wednesday, April 22, 2026 at 8:00am EDT to discussToronto, Ontario--(ACN Newswire via SeaPRwire.com - April 22, 2026) - TMX Group Limited (TSX: X) (TMX Group) announced today an agreement to acquire Middlebury Holdings Pty. Limited (Cboe Australia) and Cboe Canada Holdings, ULC (Cboe Canada) from Cboe Global Markets, Inc. for US$300 million ($409 million*) in total consideration, a transaction that will bolster TMX's ability to serve clients across the capital markets ecosystem, expand the company's global presence, and accelerate the company's growth strategy, while reducing cost and complexity for Canadian market participants."We are tremendously excited to announce the acquisition of Cboe Australia and Cboe Canada, a deal that represents a unique opportunity to strengthen our domestic marketplace for clients and the entire stakeholder ecosystem, while expanding the reach and impact of our presence in a region of the world we know well," said John McKenzie, Chief Executive Officer, TMX Group. "We look forward to working with our industry partners to ensure a smooth transition, and to exploring innovative ways to serve the needs of issuers and investors across the Australian market, while continuing to seek out opportunities to accelerate our enterprise growth strategy."Cboe Australia and Cboe Canada offer equities trading venues, listing venues and market data solutions. Cboe Australia is an innovative securities exchange offering companies strategic tailored support for public market listings, including ETFs, as well as structured products and warrants, and providing a trading venue for brokers and investors with efficient and cost-effective access to local and global investment opportunities. Cboe Australia was also recently granted a license for corporate listings. Cboe Canada includes MATCHNow, NEO-L, NEO-N, and NEO-D, as well as ETF, CDR and corporate listings."The teams at Cboe Australia and Cboe Canada have delivered consistent performance and built resilient, high-quality markets," said Craig Donohue, Chief Executive Officer, Cboe Global Markets. "These businesses are well positioned for their next chapter, and we will work closely with TMX, our local regulators, and our clients to ensure a seamless transition."Transaction HighlightsTMX's acquisition of Cboe Australia will bring together the world's leading mining and energy transition financing ecosystems, unlocking potential to innovate for a growing global client base.TMX's acquisition of Cboe Canada enhances the quality of client experience across domestic equities marketplaces:Increasing efficiency of access to capital and liquidity for Canadian issuers, andReducing direct and indirect costs for participants, while improving execution quality and resiliency.Transaction expected to be accretive to adjusted earnings per share within the first 12 months of closing, excluding synergies.Revenue growth expected to be in-line with TMX's long-term financial objectivesCombined Cboe Canada and Cboe Australia businesses delivered revenue of approximately $87 million in 2025, and adjusted EBITDA of approximately $25 million**.Further Transaction DetailsThe purchase of each business is subject to regulatory approvals and customary closing conditions in Australia and Canada. The two components of this acquisition, Cboe Australia and Cboe Canada, are expected to close separately, each after required approvals have been obtained.Canaccord Genuity and Macquarie Capital are acting as financial advisors to TMX Group. FGS Longview is acting as strategic communications advisor to TMX Group.*Based on USD/CAD exchange rate of 1.3644 at April 21, 2026. Actual amounts in Canadian dollars are subject to change.**Based on average AUD/CAD of 0.90 for 2025. Cboe Australia and Canada revenue and EBITDA are compilations of financial information provided to us for the Cboe entities as of December 31, 2025. The Cboe financial information is unaudited and prepared in accordance with IFRS (Cboe Canada) or Australian Accounting Standards (Cboe Australia) for public companies.Teleconference / Audio WebcastTMX Group will host a teleconference / audio webcast to discuss the transaction.Time: 8:00 a.m. - 9:00 a.m. ET on Wednesday, April 22, 2026Participants may access the conference call via the webcast link: https://www.gowebcasting.com/14669.The audio webcast of the conference call and investor presentation will also be available on TMX Group's website at www.tmx.com, under Investor Relations.Alternatively, participants may join the live call by dialing 1-833-752-4317 or 1-647-846-2266.An audio replay of the conference call will be available at 1-855-669-9658 or 1-412-317-0088, [access code 6830744].Caution Regarding Forward-Looking InformationThis press release of TMX Group Limited ("TMX Group", "us", "we", "our") contains "forward-looking information" (as defined in applicable Canadian securities legislation) that is based on expectations, assumptions, estimates, projections and other factors that management believes to be relevant as of the date of this press release. Often, but not always, such forward-looking information can be identified by the use of forward-looking words such as "plans", "expects", "projects", "is expected", "projected", "budget", "scheduled", "targeted", "estimates", "forecasts", "intends", "anticipates", "believes", or variations or the negatives of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved or not be taken, occur or be achieved. Forward-looking information, by its nature, requires TMX Group to make assumptions and is subject to significant risks and uncertainties which may give rise to the possibility that our expectations or conclusions will not prove to be accurate and that our assumptions may not be correct. Examples of forward-looking information in this press release include, but are not limited to, the anticipated benefits of the transactions to TMX Group, Cboe Canada and Cboe Australia; the expected impact on TMX Group's earnings and Adjusted earnings per share; expectations regarding the revenue growth of Cboe Canada and Cboe Australia; the ability to integrate Cboe Canada and Cboe Australia into TMX Group and the potential synergies; the expected impact on TMX's long-term growth strategy and transformational objectives; the potential for geographic expansion; the ability for TMX Group to accelerate Cboe Canada and Cboe Australia's growth; the timing and receipt of regulatory approval; and closing of the transaction, each of which is subject to a number of significant risks and uncertainties. These risks include, but are not limited to: competition from other exchanges or marketplaces, including alternative trading systems and new technologies, on a national and international basis; dependence on the economies of Canada, the United States and Australia; adverse effects on our results caused by global economic conditions (including geopolitical events, interest rate movements or threats of recession) or uncertainties including changes in business cycles that impact our sector; failure to retain and attract qualified personnel; geopolitical and other factors which could cause business interruption; dependence on information technology; vulnerability of our networks and third party service providers to security risks, including cyber attacks; failure to properly identify or implement our strategies; regulatory constraints; constraints imposed by our level of indebtedness, risks of litigation or other proceedings; dependence on adequate numbers of customers; failure to develop, market or gain acceptance of new products; failure to close and effectively integrate acquisitions, including the Cboe Canada and Cboe Australia acquisition, to achieve planned economics or divest underperforming businesses; currency risk; adverse effect of new business activities; adverse effects from business divestitures; not being able to meet cash requirements because of our holding company structure and restrictions on paying inter-corporate dividends; dependence on third party suppliers and service providers; dependence of trading operations on a small number of clients; risks associated with our clearing operations; challenges related to international expansion; restrictions on ownership of TMX Group common shares; inability to protect our intellectual property; adverse effect of a systemic market event on certain of our businesses; risks associated with the credit of customers; cost structures being largely fixed; the failure to realize cost reductions in the amount or the time frame anticipated; dependence on market activity that cannot be controlled; the regulatory constraints that apply to the business of TMX Group and its regulated subsidiaries, costs of on exchange clearing and depository services, trading volumes (which could be higher or lower than estimated) and the resulting impact on revenues; future levels of revenues being lower than expected or costs being higher than expected.Forward-looking information is based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions with respect to the impact of the cost of acquisition financing on adjusted earnings per share; assumptions in connection with the ability of TMX Group to successfully compete against global and regional marketplaces and other venues; business and economic conditions generally; exchange rates (including estimates of exchange rates from Canadian dollars to the U.S. dollar, British pound sterling, or Australian dollar), commodities prices, the level of trading and activity on markets, and particularly the level of trading in TMX Group's key products; business development and marketing and sales activity; the continued availability of financing on appropriate terms for future projects; changes to interest rates and the timing thereof; productivity at TMX Group, as well as that of TMX Group's competitors; market competition; research and development activities; the successful introduction and client acceptance of new products and services; successful introduction of various technology assets and capabilities; the impact on TMX Group and its customers of various regulations; TMX Group's ongoing relations with its employees; and the extent of any labour, equipment or other disruptions at any of its operations of any significance other than any planned maintenance or similar shutdowns.In addition to the assumptions outlined above, forward looking information related to long term revenue CAGR objectives, and long term adjusted earnings per share CAGR objectives are based on assumptions that include, but not limited to:TMX Group's success in achieving growth initiatives and business objectives;continued investment in growth businesses and in transformation initiatives including next generation technology and systems;no significant changes to our effective tax rate, and number of shares outstanding;organic and inorganic growth in recurring revenuemoderate levels of market volatility over the long term;level of listings, trading, and clearing consistent with historical activity;economic growth consistent with historical activity;no significant changes in regulations;continued disciplined expense management across our business;continued re-prioritization of investment towards enterprise solutions and new capabilities;free cash flow generation consistent with historical run rate; anda limited impact from inflation, rising interest rates and supply chain constraints on our plans to grow our business over the long term including on the ability of our listed issuers to raise capital.While we anticipate that subsequent events and developments may cause TMX Group's views to change, TMX Group has no intention to update this forward-looking information, except as required by applicable securities law. This forward-looking information should not be relied upon as representing TMX Group's views as of any date subsequent to the date of this press release. TMX Group has attempted to identify important factors that could cause actual actions, events or results to differ materially from those current expectations described in forward-looking information. However, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended and that could cause actual actions, events or results to differ materially from current expectations. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. These factors are not intended to represent a complete list of the factors that could affect TMX Group. Important additional information identifying risks and uncertainties and other factors is contained in TMX Group's 2025 Annual Report under the headings entitled "Caution Regarding Forward-Looking Information" and "Enterprise Risk Management" which may be accessed at tmx.com in the Investor Relations section under Regulatory Filings.Non-GAAP Financial MeasuresThis press release includes references to financial measures that are not defined by GAAP. Although such non-GAAP measures are calculated according to accepted industry practice, such measures disclosed in this press release may be different from non-GAAP measures used by other companies. This data is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. While TMX Group believes these measures provide investors with greater transparency and supplemental data relating to the transaction, readers are cautioned that these non-GAAP measures are not alternatives to measures determined in accordance with GAAP and should not, on their own, be construed as indicators of TMX Group's or Cboe Canada and Cboe Australia's future performance or profitability. Readers should not rely on any single financial measure when evaluating TMX Group's business or that of Cboe Canada and Cboe Australia. We use non-GAAP measures and non-GAAP ratios that do not have standardized meanings prescribed by GAAP and are, therefore, unlikely to be comparable to similar measures presented by other companies. Management uses these measures, and excludes certain items, because it believes doing so provides investors a more effective analysis of underlying operating and financial performance, including, in some cases, our ability to generate cash and our ability to repay debt. Management also uses these measures to more effectively measure performance over time, and excluding these items increases comparability across periods. The exclusion of certain items does not imply that they are non-recurring or not useful to investors.Adjusted earnings per share provided above is a non-GAAP ratio and does not have a standardized meaning prescribed by GAAP and is therefore unlikely to be comparable to similar measures presented by other companies. TMX Group presents Adjusted EPS and excludes, among other things, acquisition, integration, and related items; amortization of intangibles related to acquisitions; strategic re-alignment expenses; dispute, litigation and related items; and other items as disclosed in TMX Group's 2025 Annual Report. For more information on Adjusted EPS, including definitions and explanations of how these measures provide useful information, refer to Non-GAAP Measures in TMX Group's 2025 Annual Report.Adjusted EBITDA is calculated as net income excluding interest expense, income tax expense, depreciation and amortization, acquisition, integration, and related costs, one-time income (loss), and other significant items that are not reflective of the underlying business operations of Cboe Canada and Cboe Australia. Cboe Canada and Cboe Australia Adjusted EBITDA is a compilation of financial information provided to us for Cboe Canada and Cboe Australia entities as of December 31, 2025. The Cboe Canada and Cboe Australia financial information is unaudited and prepared in accordance with IFRS (Cboe Canada) or Australian Accounting Standards (Cboe Australia) for public companies. Adjusted EBITDA for Cboe Canada and Cboe Australia excludes certain items such as discontinued operations, transfer pricing, unrealized gains / losses, and one-time employee costs.About TMX Group (TSX: X) TMX Group operates global markets, and builds digital communities and analytic solutions that facilitate the funding, growth and success of businesses, traders and investors. TMX Group's key operations include Toronto Stock Exchange, TSX Venture Exchange, TSX Alpha Exchange, The Canadian Depository for Securities, Montréal Exchange, Canadian Derivatives Clearing Corporation, TSX Trust, TMX Trayport, TMX Datalinx, TMX VettaFi and TMX Newsfile, which provide listing markets, trading markets, clearing facilities, depository services, technology solutions, data products and other services to the global financial community. TMX Group is headquartered in Toronto and operates offices across North America (Montréal, Calgary, Vancouver and New York), as well as in key international markets including London, Singapore, and Vienna. For more information about TMX Group, visit www.tmx.com. Follow TMX Group on X: @TMXGroup.For more information please contact:Catherine KeeHead of Media RelationsTMX Group416-671-1704catherine.kee@tmx.comAmanda TangHead of Investor RelationsTMX Group416-895-5848amanda.tang@tmx.com To view the source version of this press release, please visit https://www.newsfilecorp.com/release/293729 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - Hengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14 billion, up 12.98% year-over-year, while net profit attributable to shareholders increased by 21.78% to RMB 2.28 billion. Innovative drugs remained the key growth driver, generating RMB 4.53 billion in revenue, up 25.75% year-over-year and accounting for 61.69% of total pharmaceutical sales.The Company continued to advance its innovation-driven strategy with sustained R&D investment and solid pipeline progress. R&D investments in Q1 2026 totaled RMB 2.22 billion, representing for approximately 27.32% of revenue.During the period, three innovative products and new indications were approved in China, which included an anti-PD-L1/TGF-βRII bi-functional fusion protein and an indication expansion for HER2-targeting ADC.In terms of pipeline advancement, the Company obtained 26 clinical trial approvals and had 8 new drug applications accepted in China across key therapeutic areas including oncology, metabolic, cardiovascular, and immunological diseases.Business development has become a recurring and increasingly important growth driver, with RMB 787 million in out-licensing revenue recognized during the quarter, primarily from the collaboration with GSK. Since 2023, Hengrui Pharma has completed 12 overseas business development transactions, including out-licensing, NewCo structures, and strategic alliance models.A key milestone during the period was the successful Nasdaq listing of Kailera Therapeutics (NASDAQ: KLRA), a NewCo company built around Hengrui Pharma’s GLP-1-based assets. This milestone reflects continued progress in executing the Company’s NewCo strategy, with Hengrui and Kailera working together to advance the global development of the GLP-1 portfolio.Looking ahead, Hengrui Pharma will remain committed to innovation and globalization, strengthening its pipeline and advancing the development and commercialization of innovative therapies to benefit patients worldwide. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TOKYO, Apr 22, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Marine Machinery & Equipment Co., Ltd. (MHI-MME) and Mitsubishi Shipbuilding Co., Ltd., both part of the Mitsubishi Heavy Industries (MHI) Group, have obtained Approval in Principle (AiP)(1) from Nippon Kaiji Kyokai (ClassNK) for the basic design of a methane oxidation catalyst system for marine LNG (liquefied natural gas)-fueled engines(2), jointly developed with Daihatsu Infinearth Mfg. Co., Ltd. A presentation ceremony was held today at Sea Japan 2026, an international maritime exhibition being held at Tokyo Big Sight in Koto-ku, Tokyo.The methane oxidation catalyst system subject to the AiP oxidizes methane slip (unburned methane) contained in the exhaust gas of marine engines. Methane has a high global warming potential among greenhouse gases (GHGs),(3) and therefore the ability to suppress its emissions is a significant advantage of this system. The system was developed with MHI-MME's catalyst design and manufacturing technology at its core, combined with Mitsubishi Shipbuilding's shipboard installation technology, and Daihatsu Infinearth's engine optimization technology.Verification testing of the catalyst system is currently being conducted in cooperation with Nippon Yusen Kabushiki Kaisha (NYK Line), with a full-scale demonstrator mounted on the KEYS Azalea, an LNG bunkering vessel(4) owned and operated by KEYS Bunkering West Japan Ltd. (KEYS). Initial measurements during the verification testing confirmed the expected performance of the exhaust gas treatment equipment, achieving a methane oxidation rate of more than 90% for the system alone.Following the acquisition of AiP and the confirmation of the expected performance through verification on an actual ship (initial measurements), the partner companies plan to further accelerate development toward commercialization of the system.MHI Group is making strategic efforts to strengthen its energy transition business. As part of this strategy, MHI-MME and Mitsubishi Shipbuilding will continue their efforts to reduce GHG emissions from marine vessels amid the growing global urgency for decarbonization, thereby contributing to the improvement of the environmental performance of ships on a global scale.(1) Approval in Principle (AiP) indicates that a certification body has reviewed the basic design of the subject equipment and confirmed that it meets technical requirements and relevant safety standards.(2) Methane oxidation is a chemical reaction in which methane (CH4) is converted into carbon dioxide (CO2) and water (H2O) through reaction with oxygen.(3) Greenhouse gases (GHGs) include carbon dioxide (CO2), methane (CH4), and nitrous oxide (N2O). The catalyst system for this demonstration test only targets methane slip.(4) LNG bunkering vessels are small ships that supply LNG fuel to LNG-fueled vessels.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Apr 22, 2026 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701) becomes the first company in the biometrics industry to receive Frost & Sullivan’s Global Biometric Solutions Company of the Year recognition(1), underscoring its leadership and innovation.Frost & Sullivan(2) bestows Best Practices Awards annually to companies that have achieved outstanding performance in their respective industries based on a rigorous analytical process. This year, NEC has been honored with the most prestigious award, the Company of the Year Award.For this Global Biometric Solutions Award, Frost & Sullivan analysts independently assessed NEC based on two criteria:Visionary Innovation & PerformanceAddressing Unmet Needs; Visionary Scenarios Through Megatrends; Leadership Focus; Best Practices Implementation; and Financial PerformanceCustomer ImpactPrice/Performance Value; Customer Purchase Experience; Customer Ownership Experience; Customer Service Experience; and Brand EquityTara Semon, Security Industry Analyst, Frost & Sullivan, said, "NEC’s achievements reflect a rare blend of technical excellence, ethical leadership, and customer-centric innovation. From pioneering multimodal authentication and ear acoustic to championing self-sovereign identity and responsible AI usage, the company has consistently delivered solutions that meet the evolving needs of a global market."Its deployments across public safety, education, and consumer experiences demonstrate the versatility and impact of its technologies. NEC’s commitment to research, ethics, and global expansion positions it as a beacon of excellence in the biometric solutions industry."In the future, NEC will continue to focus on replacing physical identity verification methods and physical security, as well as accelerating the development and provision of solutions that can be adapted to new use cases in an ever-growing digital society.NEC is thoroughly committed to following the NEC Group AI and Human Rights Principles(3) in its use of AI, biometric data, and other data, placing the highest priority on privacy and respect for human rights.NEC offers end-to-end digital transformation (DX) services, from strategy and concept consulting to implementation-focused offerings, based on the three pillars of business models, technology, and organization/talent. Additionally, in its shift from a traditional systems integrator to a "Value Driver," NEC restructured its value creation model under the name "NEC BluStellar"(4), which leverages NEC's cutting-edge technologies, developed and refined through years of experience and proven cross-industry expertise, aiming to transform business models, address social challenges, resolve management issues faced by customers, and lead them into a brighter future.For more information about third-party recognition of NEC’s biometric authentication, please visit here.(1) Frost & Sullivan Best Practices 2026 Recognition Recipients(2) Frost & Sullivan - The Transformational Growth Company(3) "NEC Group AI and Human Rights Principles" https://www.nec.com/en/press/201904/global_20190402_01.html(4) NEC BluStellar is a value creation model that leverages NEC’s cutting-edge technologies, developed and refined through years of experience and proven cross-industry expertise. It aims to transform business models, address social challenges, resolve management issues faced by customers, and lead them into a brighter future.About NECThe NEC Group leverages technology to create social value and promote a more sustainable world where everyone has the chance to reach their full potential. NEC Corporation was established in 1899. Today, the NEC Group’s approximately 110,000 employees utilize world-leading AI, security, and communications technologies to solve the most pressing needs of customers and society.For more information, please visit https://www.nec.com.  Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

HONG KONG, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - Apr 20, Everest Medicines announced that the first-in-human (FIH) clinical trial data of EVM16, a proprietary personalized mRNA cancer vaccine, were presented at the 2026 American Association for Cancer Research  Annual Meeting (AACR 2026). The data include results from EVM16 as  a monotherapy and in combination with the PD-1 inhibitor tislelizumab in patients with advanced solid tumors. The results demonstrated that EVM16 has a favorable safety and tolerability profile, robust immunogenicity, and promising preliminary efficacy in patients with advanced solid tumors, supporting its further clinical development.The clinical trial (EVM16CX01, NCT06541639) was conducted jointly by Peking University Cancer Hospital and Fudan University Shanghai Cancer Center, with the first patient dosed in March 2025. EVM16CX01 is a first-in-human (FIH), dose-escalation, and expansion study evaluating the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 injection as a monotherapy and in combination with tislelizumab in patients with advanced solid tumors. The study follows a 3+3 dose-escalation design across three dose levels (0.1 mg, 0.3 mg, and 1.0 mg). Eligible patients are those with advanced or recurrent solid tumors who have failed standard of care and have at least one measurable target lesion. Patients receive 2 doses of EVM16 monotherapy once every two weeks, followed by combination therapy of EVM16 and tislelizumab. As of December 7, 2025, a total of 9 patients had been enrolled.No dose-limiting toxicities (DLTs) were observed. All patients experienced at least one investigational product (IP) related adverse event (AE), all of which were Grade ≤ 2 and resolved spontaneously. EVM16 elicited strong neoantigen-specific T cell responses in 8 of 9 patients, which showed a dose-dependent trend. A gastroesophageal junction cancer patient who failed 3 prior lines of systemic therapy achieved a confirmed partial response and a PFS of 126 days. Another 2 patients achieved stable disease. A non-small cell lung cancer patient who failed 3 prior lines of systemic therapy achieved a PFS of 88 days, and an esophageal squamous cell carcinoma patient who failed 3 prior lines of systemic therapy has been followed up for 112 days to date and has not experienced disease progression.“As a novel personalized mRNA cancer vaccine, EVM16 has demonstrated encouraging clinical development potential in its first-in-human clinical trial,” said Professor Shen Lin, Director of the Gastrointestinal Oncology Department at Beijing Cancer Hospital and Chair of the Gastric Cancer Expert Committee of the Chinese Society of Clinical Oncology. “The data show a favorable safety and tolerability profile in patients with advanced solid tumors, with no dose-limiting toxicities (DLTs) observed. Importantly, EVM16 stimulated neoantigen-specific T cell responses with a dose-dependent trend, highlighting its consistent immune activation capability. Preliminary anti-tumor activity signals, including partial response (PR) and stable disease (SD), were observed in patients who had failed multiple lines of standard-of-care therapies, suggesting potential clinical activity. These findings provide early clinical validation of EVM16 and reinforce its differentiated mechanism as a personalized mRNA cancer vaccine. While immunotherapies, including checkpoint inhibitors, have transformed the treatment landscape in selected tumor types, most patients, particularly those with heavily pretreated advanced solid tumors, still represent a significant unmet medical need. Personalized mRNA cancer vaccines represented by EVM16 may help expand the population benefiting from immunotherapy and provide additional treatment options.” “The favorable safety, tolerability, immunogenicity, and preliminary efficacy results for EVM16 provide initial evidence of its therapeutic potential and support the clinical value of our in-house mRNA platform,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Patients with advanced solid tumors, particularly those who have failed multiple lines of therapy, continue to suffer from limited treatment options. As our first in-house developed personalized mRNA cancer vaccine, EVM16 demonstrates the ability to induce immune activation and generate neoantigen-specific T cell responses, which may help reduce the risk of tumor metastasis or recurrence. This further underscores its potential as a novel approach in cancer immunotherapy. This project is powered by EVER-NEO-1, Everest’s proprietary AI-based neoantigen prediction algorithm. It analyzes patient-specific tumor mutations to identify highly immunogenic neoantigens and support the design of personalized mRNA vaccine candidates. The algorithm incorporates iterative learning capabilities designed to continuously improve neoantigen prediction accuracy and selection efficiency. Leveraging our leading mRNA platform, we will continue to advance the clinical development of EVM16 and bring this innovative therapy to more patients.”Everest Medicines has localized its clinically validated proprietary AI+mRNA platform, establishing an end-to-end integrated platform spanning antigen design, mRNA sequence optimization, lipid nanoparticles (LNP) targeted delivery and scalable manufacturing, with the potential to address significant unmet medical needs globally.EVM16 is a novel personalized therapeutic mRNA cancer vaccine in-house developed by Everest. It contains neoantigens with high immunogenicity potential, predicted based on the unique tumor mutations of each patient using Everest’s proprietary AI-based neoantigen prediction algorithm, EVER-NEO-1. The vaccine is designed to encode dozens of tumor neoantigens. The vaccine uses a lipid nanoparticle (LNP) delivery system to efficiently deliver neoantigen-encoded mRNA in vivo, activating neoantigen-specific tumor-killing T cells and inhibiting tumor growth.From an investment and market perspective, personalized cancer vaccines are in an early stage of breakthrough. According to Grand View Research, the global personalized cancer vaccine market is projected to reach $1.45 billion by 2030, with a staggering compound annual growth rate (CAGR) of 44.86% from 2025 to 2030. Myguide Securities points out that mRNA cancer vaccines have the potential to achieve pan-cancer coverage while offering the advantages of high accessibility, “off-the-shelf” availability, and personalization. As a highly promising new form of immunotherapy, it can enter clinical use as adjuvant therapies through extensive combinations, gradually unlocking a market space worth tens of billions of dollars.Against this backdrop, Everest Medicines is accelerating its strategic positioning in this field, progressively building a research and development pipeline with global competitiveness. Leveraging its proprietary AI+mRNA platform and its leading clinical position in China, Everest Medicines is currently at a critical juncture for industrialization and valuation growth. The upcoming readout of first-in-human (FIH) clinical trial data for EVM16 is expected to further release clinical and commercial potential, continuing to attract focus from the market and investors, and helping the company achieve a significant leap in value within the immunotherapy sector. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Hokubu Waste-to-Energy PlantTOKYO, Apr 22, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Environmental & Chemical Engineering Co., Ltd. (MHIEC), a part of Mitsubishi Heavy Industries (MHI) Group, has recently completed the improvement of core equipment for Hokubu Waste-to-Energy Plant, a municipal solid waste incineration facility in Kagoshima City. The work consisted of renovation of the stoker type incinerators, capable of processing 530 tonnes per day (tpd) (1), to extend the plant's service life and reduce CO2 emissions. This was a project spanning a six-year period from fiscal 2020 to fiscal 2025.The Hokubu Waste-to-Energy Plant was originally designed and constructed by MHI, and completed in March 2007. It comprises two units of stoker type incinerators, each with processing capacity of 265 tpd, plus related equipment, delivering power generation capacity of 8,700 kW.Under the refurbishment work, upgrades have been made to deteriorated major equipment, to achieve stable combustion and operation over the long term. Additionally, a low-temperature catalyst, a proprietary technology of MHIEC, was introduced to the SCR (Selective Catalytic NOx Reduction) system to improve the heat recovery rate (2), a low excess air ratio incineration technology (3) was adopted to improve combustion and the efficiency of the boiler, and the output of the steam turbines was increased from 8,700 kW to 10,005 kW, which will reduce CO2 emissions by approximately 33.1% per year.MHIEC took over MHI's waste treatment plant business in 2008, acquiring the technological development capabilities in environmental systems and broad-ranging expertise in the construction and operation of waste management facilities both in Japan and overseas that MHI honed over many years. A strength of this company is its ability to propose total solutions from construction to operation based on its extensive track record. Going forward, MHIEC will continue to proactively make proposals to extend the life of existing waste treatment facilities, take measures against global warming, and reduce lifecycle costs (LCC) such as maintenance and management costs to contribute to the decarbonization of energy through the collection of energy from waste.(1) A stoker-type incinerator injects air from beneath heat-resistant fire grates, mixing the waste and other material by pushing it up, and allowing for efficient incineration. It is the most common system used for municipal solid waste.(2) An SCR system removes nitrous oxides (NOx), an air pollutant in exhaust gases, and typically operates at a high temperature. With MHIEC's technology, a catalyst that can remove NOx at low temperatures was introduced to the SCR system, eliminating the need to heat the exhaust gas to a high temperature and increasing the heat recovery rate.(3) The volume of air required for combustion is suitably distributed to reduce the volumes of combusted air and exhaust gas, increasing the efficiency of the boiler and decreasing the energy consumption of the induced draft fan.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Matsumori Waste-to-Energy PlantTOKYO, Apr 22, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Environmental & Chemical Engineering Co., Ltd. (MHIEC), a part of Mitsubishi Heavy Industries (MHI) Group, has recently completed the improvement of core equipment for Matsumori Waste-to-Energy Plant, a municipal solid waste incineration facility in Sendai City. MHIEC received the contract for the project from Sendai City in 2021, with work carried out over a five-year period from fiscal 2021 to fiscal 2025. The renovation of the stoker-type incinerators(1) with total processing capacity of 600 tons per day (tpd) will extend the operational life of the facility and reduce CO2 emissions.The Matsumori Waste-to-Energy Plant was originally designed and constructed by MHI, and completed in August 2005. It comprises three units of stoker-type incinerators, each with processing capacity of 200 tpd, plus related equipment, delivering power generating capacity of 17,500 kW.Under the refurbishment work, upgrades have been made to major equipment superannuated after more than 15 years in operation, to achieve stable combustion and operation over the long term. In addition, the thermal efficiency of the boiler has been enhanced with the introduction of EGR-PLUS®, a new combustion control system using an exhaust gas recirculation technology.(2) Further, a part of the soot blower that removes ash from the boiler tube has been changed from a conventional steam type to a pressure-wave (shock pulse) type,(3) reducing the amount of steam used for ash removal and allowing more steam for power generation, thereby boosting power generating capacity. These renovations have achieved a reduction in CO2 emissions of 12.1% annually.MHIEC took over the waste treatment plant business from MHI in 2008, acquiring technological development capabilities in environmental systems and broad-ranging expertise in the construction and operation of waste management facilities both in Japan and overseas. This extensive experience allows MHIEC to provide comprehensive solutions, from plant construction to operations. Going forward, MHIEC will continue to proactively make proposals to extend the life of existing waste treatment facilities, take measures against global warming, and reduce lifecycle costs (LCC) such as maintenance and management costs to contribute to the decarbonization of energy through the collection of energy from waste.(1) A stoker-type incinerator injects air from beneath heat-resistant fire grates, mixing the waste and other material by pushing it up, and allowing for efficient incineration. It is the most common system used for municipal solid waste.(2) Exhaust Gas Recirculation (EGR) is a technology to send exhaust gas from the incinerator back into the combustion chamber, promoting complete combustion and reducing nitrogen oxide (NOx) emissions. MHIEC's EGR-PLUS® is a leading-edge combustion control system that combines EGR with low air ratio (the amount of air actually sent to the incinerator divided by the minimum amount of air theoretically required for incineration) combustion technology to reduce the environmental impact, and achieve a stable increase in the amount of electricity sold.(3) A pressure-wave (shock pulse) type soot blower is a device that removes ash from pipes by igniting a mixture of methane and oxygen and firing it into the combustion chamber from an injection nozzle, creating a pressure wave that breaks up ash deposits and causes fine vibrations on the pipe surface.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

HONG KONG, Apr 21, 2026 - (ACN Newswire via SeaPRwire.com) - Seven annual lifestyle and licensing mega events organised by the Hong Kong Trade Development Council (HKTDC) are set to open next week. These include the Hong Kong Gifts & Premium Fair, Home InStyle and Fashion InStyle on 27-30 April at the Hong Kong Convention and Exhibition Centre, HKCEC; and the Hong Kong International Printing & Packaging Fair and DeLuxe PrintPack Hong Kong co-organised by the HKTDC and CIEC Exhibition Company (HK) Limited, held concurrently at AsiaWorld-Expo on 27-30 April; and the Hong Kong International Licensing Show and Asian Licensing Conference on 27-29 April at the HKCEC.Global exhibitors will showcase offerings spanning gifts and premiums, stylish houseware, trendy fashion, innovative materials for garment and homeware, gerontechnology, cultural and creative design products, sustainable products, green printing and packaging and intellectual property. The events fully leverage Hong Kong's unique connectivity between Chinese Mainland and international markets, reinforcing the city's position as a regional creative hub and international business centre, and actively aligning with the national 15th Five-Year Plan and dual circulation development strategy.HKTDC Deputy Executive Director Jenny Koo said: "The HKTDC has long facilitated trade exchanges across industries through organising a wide range of conferences and exhibitions, fulfilling Hong Kong's roles as a super connector and super value-adder while showcasing its strengths in new quality productive forces, product quality and creativity. This year, the seven mega lifestyle and licensing exhibitions and conference are being held concurrently during the final week of April. Buyers can enjoy a one-stop sourcing experience across all fairs, fostering cross-industry and cross-sectoral exchanges, generating greater synergies, and helping expand customer bases and business opportunities."The seven mega exhibitions and conference are expected to attract some 5,600 exhibitors from more than 30 countries and regions, including Hong Kong, Chinese Mainland, Asia, Europe and the Middle East. First-time exhibitors this year include participants from Finland, Germany, Iceland, the United Arab Emirates and Uzbekistan.Home InStyle welcomes new pavilions from Xinjiang and Wuhan; The Gifts & Premium Fair features new pavilions from Shanxi, Jilin, Huangnan Tibetan Autonomous Prefecture and Zhejiang, with the Zhejiang pavilion, organised for the first time by the Zhejiang Provincial Department of Commerce, bringing together 50 local enterprises. The Printing & Packaging Fair includes a new Fujian Quanzhou pavilion and Fashion InStyle features new pavilions from Jiangsu Sheyang, India and Indonesia, offering buyers an even more diverse range of sourcing options.The HKTDC continues to encourage the industry to embrace sustainable development and promote the use of innovative materials. This year, the seven fairs will collectively bring together over 820 green exhibitors. In addition, approximately 80 exhibitors will showcase innovative material products spanning houseware, home textiles, fashion, printing and packaging, and other sectors.Reimagine themed floor converges gifts and homeware creative inspirationIn keeping with market developments, HKCEC Hall 5 has transformed into aReimagine themed floor this year. The Reimagine floor presents a new vision of future lifestyles by seamlessly connecting the innovative, design and cultural creative elements of both the Gifts & Premium Fair and Home InStyle. This enables buyers to gain a one-stop overview of the latest global lifestyle homeware and gifting trends, while inspiring industry players to reimagine the boundless possibilities of future products and creative inspiration. The floor has several highlighted zones, including the Gifts & Premium Fair's new Selection of ASEAN and The Bespoke Hub and the Hong Kong Smart Design Global Awards, Home InStyle's Cultural and Creative Avenue and Gerontech and Innovative Material Pavilion.The Hong Kong Smart Design Global Awards, organised by the Hong Kong Exporters’ Association and sponsored by the Cultural and Creative Industries Development Agency (CCIDA), is renamed this year in recognition of Hong Kong's original design talent. The grand finale will be held during the Gifts & Premium Fair, with all finalist entries displayed on-site, giving exhibitors direct access to international buyers to enhance brand visibility and expand collaboration opportunities.The Cultural and Creative Avenue brings together over 110 exhibitors from over 10 countries and regions, presenting distinctive brands and designs that celebrate diverse cultural heritages. The zone once again partners with Pantone, using the PANTONE 2026 Colour of the Year "Cloud Dancer" as its theme to curate home décor settings, helping buyers understand how colour coordination can be harnessed to create stylish living spaces.Innovative materials debut at Home InStyleGlobal ageing is driving sustained growth in silver market demand, with the industry actively developing gerontechnology living products and solutions incorporating smart technologies to support home fitness, rehabilitation and daily living needs. Meanwhile, the development and application of innovative materials have also become a focal point in the homeware market. In response to these trends, Home InStyle will showcase innovative materials applied to the homeware and home textiles market for the first time this year. Building on the success of last year's gerontech living product showcase, both elements have been brought together in the Gerontech and Innovative Material Pavilion, funded by the Innovation and Technology Commission, with over 20 local exhibitors joining to inject fresh innovation into the homeware market.A series of events will also be held during the fairs, covering the silver economy, market trends, culture and innovation, and sustainability, helping the industry stay abreast of the latest market developments. Among them, the HKTDC, will co-organise a thematic seminar with the Federation of Hong Kong Industries (FHKI) and the Hong Kong Q-Mark Council, inviting representatives from the FHKI, the Hong Kong Council of Social Service and technology experts, to explore how to respond to the silver market through the introduction of the "Silver Q Mark" and certified gerontech living products. On sustainability, the Business Environment Council and representatives from eco-conscious enterprises will also analyse trends and breakthroughs in sustainable home and gift design.Fashion InStyle reveals how diverse materials collide to drive fashion innovationFashion InStyle features multiple exhibition zones, including Designer Spotlight, Materials Bazaar, Fashion Accessories, Women in Style, Bridal & Evening Wear, and Athleisure, etc. Among them, NEXT@Fashion InStyle (NEXT), the highlighted zone organised by HKTDC and sponsored by the Cultural and Creative Industries Development Agency (CCIDA) of the Hong Kong SAR Government, returns in full force this year, demonstrating how materials innovation in fashion can drive industry transformation and advance sustainability.This year, the Philippines is NEXT's featured partner, powered by The Philippine Trade and Investment Centre – Hong Kong (PTIC-HK) and the Center for International Trade Expositions and Missions (CITEM), more than 25 Philippine exhibitors showcasing the unique strengths of their local fashion materials. NEXT has also brought together over 60 global exhibitors from an ever-wider geographical reach, spanning not only Hong Kong, Chinese Mainland and the Philippines, but also other Asian markets such as Indonesia and Thailand. This year, several Nordic countries join the showcase, including Iceland, Finland and Sweden, further elevating NEXT's international profile and cementing its role as a global exchange platform for leading future fashion trends.NEXT has once again invited Han Chong, founder and creative director of contemporary fashion brand Self-Portrait, to serve as the project ambassador. Chong will lead six local designer brands in selecting forward-looking materials from eight suppliers to develop five cross-disciplinary design projects. This year marks the first time that materials sourced from outside Hong Kong are incorporated into the designs. The collections explore three overarching themes namely cultural & heritage, sustainability, and technology and functionality. All completed designs will be unveiled at the NEXT Fashion Parade on the second evening of the Fair (28 April).Two PrintPack Fairs present latest trends of smart technology and green packagingThis year's Printing & Packaging Fair introduces new products and solutions in smart packaging and innovative materials, with a spotlight on advanced RFID and anti-counterfeiting packaging technologies. Some exhibitors will also present packaging products made from plant-based or bio-based materials. The popular Green Printing & Packaging Solutions Zone returns once again, facilitating buyers identify packaging options that are more eco-friendly, efficient and practical.DeLuxe PrintPack Hong Kong focuses on premium printing and packaging solutions for high-end goods including jewellery, watches, cosmetics and fine wine. Many exhibitors will showcase distinctive packaging designs for six-star hotels and luxury brands, highlighting exceptional craftsmanship and refined brand aesthetics. The two fairs will also feature a series of seminars covering AI, sustainability and creative design. Representatives from FUJIFILM and BW Design Centre will share insights into the application of AI in printing and design. On the sustainability front, seminars will explore on new materials, smart technologies and innovative design in packaging, examining how the industry can enhance sustainability through the adoption of advanced materials. On creative design, renowned designers will discuss how design excellence, strong brand imagery and innovative elements can elevate product appeal and reinforce brand distinction.Hong Kong International Licensing Show and Asian Licensing Conference connect global opportunities  Now in its 23rd edition, the Hong Kong International Licensing Show, Asia's flagship licensing event, brings together over 600 brands and intellectual properties (IPs) from multiple countries and regions, including Bandai Namco, Doraemon and LINE FRIENDS, spanning licensing categories such as arts and culture, animation and characters, brand extension, entertainment, lifestyle and sports. The event serves as a cross-regional and cross-sectoral business expansion platform for global licensors, brands and IP owners worldwide.The Design Licensing and Business (DLAB) Support Scheme, organised by the Innovative Entrepreneur Association (IEA) and sponsored by the CCIDA of the HKSAR Government, will once again participate in the Licensing Show. The dedicated DLAB Hong Kong Pavilion will showcase close to 40 local IPs and brands. Some IPs, including Animomo and Emo Neko Club, tap into the increasingly popular "emotional economy" concept, forging deeper emotional connections with consumers through emotional value, nostalgic elements and heartwarming stories. The Hong Kong Licensing Force Showcase also returns, collaborating with Hang Seng University of Hong Kong, Hong Kong Baptist University, Hong Kong Design Institute and The Hong Kong Polytechnic University to showcase innovative licensing concepts and design prowess of the next generation of creative talent.As e-commerce economy continues to flourish and IP market sales models continue to evolve, the show introduces for the first time a dedicated "IP and e-Commerce Support Services" Zone.  Aligned with the HKSAR Government’s policy direction to actively enhance Hong Kong companies’ competitiveness on cross-border e-commerce platforms, it brings together e-commerce platforms, KOLs, marketing and PR firms to help brands and IPs expand into e-commerce markets and capitalise on online business opportunities.The concurrent Asian Licensing Conference, under the theme "Connecting Creativity, Unlocking Licensing Power", brings together industry leaders to explore the latest developments and opportunities in the global licensing market. Key topics this year include "Global Licensing Trends to Watch in 2026", "Perfectly Imperfect: The Rise of Fugglers in the Emotional Economy", Winning Off the Field: The Business Strategy behind Successful Sports Licensing", "The LBE Revolution: Engaging Audiences Beyond the Screen" and "VTubers: Redefining Entertainment in the Digital Age", offering the industry forward-looking insights and analysis.EXHIBITION+ Integrates online and offline experiences; AI boosts sourcing efficiencyThe seven exhibitions and conference continue to adopt the EXHIBITION+ hybrid format. In addition to the physical fairs, the “Click2Match” will leverage AI to provide business matching for exhibitors and buyers. Buyers can also use “Scan2Match” to scan exhibitors' QR codes, bookmark exhibitors and continue discussions online during or after the fairs. The fairs will also introduce an AI-driven SmartBot service on-site for the first time, enabling buyers to search more swiftly for products and exhibitors and instantly generate personalized visit routes.Photo Download: http://bit.ly/3OSQRvFIntroducing highlights of the seven lifestyle and creative events at today’s press conference were (from left to right) Katherine Fang, Chairman of the HKTDC Garment Advisory Committee; Jeffrey Lam, Chairman of the HKTDC Home InStyle and Hong Kong Gifts & Premium Fair Organising Committee; Jenny Koo, Deputy Executive Director of the HKTDC; Helena Chiu, Chairman of the Hong Kong Exporters' Association; and Zacharias Cheng, President of the Innovative Entrepreneur Association (IEA)Hong Kong Gifts & Premium Fair exhibitor Wei Yit Vacuum Flask Manufactory Ltd unveils its new Series 116 vacuum flask blind box, designed by Hong Kong illustrator Pen So and Hong Kong contemporary artist Jerry Cho. Each piece features intricately illustrated Hong Kong streetscapes, making it highly collectibleHome InStyle exhibitor features a smart fitness training system at the Gerontech and Innovative Material Pavilion. Powered by AI and data-driven training, the system collects and analyses user data to formulate personalised exercise plans, enabling seniors to build strength at homeNEXT@Fashion InStyle features designs that offer contemporary reinterpretations of cultural heritage. Design studio Tigerstrolling fuses Song Brocade, a national-level intangible cultural heritage, with denim, while weaving in Hong Kong cultural elements to breathe fresh street energy into the intangible cultural heritage traditionHong Kong International Printing & Packaging Fair exhibitor introduces eco-friendly wet-pressed pulp moulded packaging boxes made primarily from wood pulp and sugarcane pulp. Biodegradable and fully recyclable, the boxes also offer moisture-proof, waterproof, oil-resistant and dust-resistant propertiesDeLuxe PrintPack Hong Kong exhibitor showcases packaging boxes made of carbon fibre. Previously used in automotive and sports equipment, the material is now being applied to lifestyle products for its lightweight and impact-resistant propertiesHong Kong International Licensing Show exhibitor presents their pixel-art IP character Potatoz and a series of products inspired by the IPEvents Details:EventsEvent DateOpening HoursVenueHong Kong Gifts & Premium Fair 27–29 Apr(Mon–Wed)30 Apr(Thu)  9:30am – 6:30pm9:30am – 5:00pm   HKCECHome InStyleFashion InStyleHong Kong International Printing & Packaging Fair27 Apr(Mon)28–29 Apr(Tue–Wed)30 Apr(Thu)10:30am –5:30pm 9:30am – 5:30pm9:30am – 3:30pm  AsiaWorld-ExpoDeLuxe PrintPack Hong KongHong Kong International Licensing Show27–28 Apr(Mon–Tue) 29 Apr(Wed) 9:30am – 6:30pm 9:30am – 5:00pm HKCECAsian Licensing ConferenceMedia enquiriesFor enquiries, please contact:Home InStyle, Fashion InStyle, HK Gifts & Premium Fair, HK International Printing & Packaging Fair and DeLuxe PrintPack Hong KongPandagon:Fraser LiTel: 6083 5623Email: pandagon.limited@gmail.comHKTDC’s Communications & Public Affairs Department:Clayton LauwTel: 2584 4472Email: clayton.y.lauw@hktdc.org   HK International Licensing Show and Asian Licensing ConferenceRaconteur:  Molisa LauTel: 6187 7786Email: molisalau@raconteur.hkBetsy TseTel: 9742 7338Email: betsytse@raconteur.hk HKTDC’s Communications & Public Affairs Department:Winnie KanTel: 2584 4055Email: winnie.wy.kan@hktdc.orgHKTDC Newsroom: http://mediaroom.hktdc.com/enAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SUNNYVALE, CA, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - Graid Technology, the pioneer in GPU-accelerated NVMe storage, today announced its Agentic AI Storage Portfolio: a purpose-built family of KV cache solutions designed to eliminate the storage bottleneck that stalls "always-on" production AI. The portfolio spans three deployment tiers: KV Cache Server, KV Cache Rack, and KV Cache Platform, all built on SupremeRAID™ technology. KV Cache Platform, the portfolio's highest tier, is purpose-aligned to NVIDIA's STX reference architecture, with native BlueField-4 DPU execution on the roadmap for H2 2026.As agentic AI moves from experimentation to production, the infrastructure assumptions that underpinned single-shot inference have broken down. Models running continuous multi-step tasks and maintaining context across hours of operation generate KV cache demands that overwhelm GPU HBM. The result: latency spikes up to 18x, GPU utilization as low as 50%, and model-level failures, including hallucinations and reasoning degradation, that are difficult to detect and costly to recover from.SupremeRAID™ addresses this directly, aggregating up to 32 NVMe drives into a single 280 GB/s virtual pool, bypassing the CPU via GPU Direct Storage, and delivering KV cache reads at 1.3ms- 77x faster than standard NVMe. The three portfolio tiers bring this capability to every deployment scale:KV Cache Server - single-node NVMe acceleration for individual inference servers and edge AI deployments. Available now.KV Cache Rack - rack-scale, partner-validated solutions co-engineered with leading server OEM partners for enterprise multi-GPU clusters. Available now.KV Cache Platform - Purpose-built for NVIDIA's STX reference architecture, with native BlueField-4 DPU execution and rack-scale storage expansion on the roadmap."A year ago, at GTC 2025, Jensen Huang predicted that storage would become GPU-accelerated for the first time. This year, NVIDIA turned that concept into an architecture with STX and CMX," said Leander Yu, CEO of Graid Technology. "Our KV Cache Portfolio is built for precisely this moment, delivering the storage performance that agentic AI demands, at storage-tier economics."For enterprises and infrastructure teams evaluating agentic AI deployments, the full deployment architecture, technical specifications, and NVIDIA STX compatibility details are available in the solution brief: Graid Technology Agentic AI Storage Portfolio: Purpose-built KV Cache Solutions for Inference at Scale.To learn more about Graid Technology's AI offerings, visit graidtech.com/ai.Media Inquiries:Andrea Eaken, Sr. Director of Marketing, Americas & EMEAandrea.eaken@graidtech.comAbout Graid TechnologyGraid Technology is building the storage backbone for the future of AI, enterprise, and high-performance computing. As the creator of SupremeRAID™, the world's first and only GPU-based RAID, and the global steward of Intel® Virtual RAID on CPU (Intel® VROC), Graid Technology delivers flexible RAID solutions that maximize NVMe performance while ensuring resilient, scalable data protection for modern data infrastructure. Headquartered in Silicon Valley with global operations and R&D in Taiwan, Graid Technology is advancing RAID innovation for the next generation of data-intensive workloads. To learn more, visit graidtech.com.SOURCE: Graid Technology Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TSUKUBA, Japan, Apr 22, 2026 - (ACN Newswire via SeaPRwire.com) - Discovering and characterizing new materials is important for unlocking advances in fields like clean energy, advanced manufacturing, and improved infrastructure. Researchers use machine learning and other computational tools to help them, but the trial-and-error nature of the process creates specific challenges. The research produces large amounts of experimental and computational data, and scientists need tools that can track and store not only the results but also the chain of reasoning behind them.A newly developed system tracks and stores not only the results but also the chain of reasoning behind them, allowing researchers to review the decision making process for a greater transparency and reproducibility in materials science research.A new system called pinax, published in the journal Science and Technology of Advanced Materials: Methods, provides precisely those features. Developed by engineers at Japan’s National Institute for Materials Science (NIMS), pinax captures the entire process of developing new materials, including machine learning workflows and decision-making processes. “By formalizing both successful and unsuccessful trial-and-error processes, pinax enhances reproducibility, accountability, and knowledge sharing while maintaining strict data governance,” says Satoshi Minamoto of NIMS, the study’s lead author.The new pinax system consists of three layers: the core machine learning infrastructure (bottom), the provenance recording and tracking that visualises the reasoning behind final results (middle), and the advanced feature layer for materials development (top). Credit: STAM-MMachine learning models are playing an ever-larger role in materials discovery and characterization. While the models are powerful tools, the reasoning processes they use are generally opaque. Researchers don’t know what considerations and trial-and-error processes went into their final predictions. “The system introduced in this study visualizes these invisible processes. This enables others to review, verify, and build upon the path to the conclusions,” says Minamoto.Minamoto highlights the importance of such access in applications where safety, reproducibility, and accountability are important, saying that this work “demonstrates how transparent AI systems can transform scientific discovery into a more reliable, efficient, and socially responsible endeavor.”The team tested pinax using two case studies: one on predicting steel properties and another using transfer learning to predict the thermal conductivity of polymers. The system made it possible to link the model’s performance predictions to the specific data or model aspects that influenced them, and to reproduce complex, multi-stage workflows. “In particular, the transfer-learning example highlights pinax’s ability to track how information flows between intertwined datasets and models, making every step in the reasoning process explicitly traceable,” says Minamoto.The engineers plan to expand pinax towards an autonomous, closed-loop materials discovery system. By integrating pinax’s tracking capabilities with automated experimental and simulation systems, they aim to create a loop that can use data generation, machine learning models, and decision-making systems to systematically and independently carry out the entire research cycle.Further information Satoshi MinamotoNational Institute for Materials Scienceminamoto.satoshi@nims.go.jpPaper: https://doi.org/10.1080/27660400.2026.2629051 About Science and Technology of Advanced Materials: Methods (STAM-M)STAM Methods is an open access sister journal of Science and Technology of Advanced Materials (STAM), and focuses on emergent methods and tools for improving and/or accelerating materials developments, such as methodology, apparatus, instrumentation, modeling, high-through put data collection, materials/process informatics, databases, and programming. https://www.tandfonline.com/STAM-MDr Kazuya SaitoSTAM Methods Publishing Director SAITO.Kazuya@nims.go.jpPress release distributed by Asia Research News for Science and Technology of Advanced Materials. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TOKYO and RAHWAY, N.J., Apr 21, 2026 - (JCN Newswire via SeaPRwire.com) - Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada), and Eisai (Headquarters: Tokyo, CEO: Haruo Naito) today announced results from the Phase 3 LITESPARK-012 trial evaluating combination treatments for the firstline treatment of patients with advanced clear cell renal cell carcinoma (RCC). The trial evaluated the triplet therapy of KEYTRUDA® (pembrolizumab), Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, plus WELIREG® (belzutifan), Merck & Co., Inc., Rahway, NJ, USA’s first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor. The study also evaluated MK-1308A, the coformulation of KEYTRUDA and quavonlimab, Merck & Co., Inc., Rahway, NJ, USA’s investigational anti-CTLA-4 antibody, plus LENVIMA. Both combination regimens were compared to KEYTRUDA plus LENVIMA for these patients.At a pre-specified interim analysis, the combination regimens did not meet the dual primary endpoints of progression-free survival (PFS) and overall survival (OS) for the first-line treatment of patients with RCC compared to KEYTRUDA plus LENVIMA. The safety profiles of the combination regimens were consistent with those observed in previously reported studies evaluating the individual medicines and the KEYTRUDA plus LENVIMA combination. A full evaluation of the data from this study is ongoing, and Merck & Co., Inc., Rahway, NJ, USA and Eisai will work with investigators to share the results with the scientific community.“With the LITESPARK-012 trial, we explored whether combining therapies with established activity could improve upon well-established standards set by KEYTRUDA-based regimens, reflecting our commitment to continuously explore ways to improve outcomes for the kidney cancer community,” said Dr. M. Catherine Pietanza, Vice President, Global Clinical Development, MSD Research Laboratories. “While these regimens did not demonstrate the results we hoped, the data deepen our understanding of advanced renal cell carcinoma and will help shape the next generation of treatment approaches.”“While we are disappointed that LITESPARK-012 did not meet its primary endpoints, the findings reinforce the central role of KEYTRUDA plus LENVIMA in the first-line treatment of patients with advanced renal cell carcinoma,” said Dr. Corina Dutcus, Senior Vice President, Oncology Global Clinical Development Lead at Eisai Inc. “Findings from trials such as this play an important role in shaping health care providers’ perspectives as the treatment paradigm for advanced renal cell carcinoma continues to evolve. We are committed to advancing the care of people living with this disease and we are grateful to the patients, caregivers and investigators whose participation and dedication made this research possible.”Results from the LITESPARK-012 trial do not affect other ongoing trials from the LITESPARK clinical program, including those conducted jointly with Eisai. As previously announced, the U.S. Food and Drug Administration (FDA) has accepted two supplemental New Drug Applications (sNDA) for review based on Phase 3 LITESPARK-011 trial evaluating WELIREG in combination with LENVIMA for certain previously treated patients with advanced RCC and has set a Prescription Drug User Fee Act (PDUFA), or target action, date of Oct 4, 2026.KEYTRUDA is currently approved as adjuvant monotherapy and in combination regimens for appropriate patients with RCC in the U.S., European Union (EU), Japan and other countries around the world.KEYTRUDA plus LENVIMA is approved in the U.S., the EU, Japan and other countries for the firstline treatment of adult patients with advanced RCC. Lenvatinib is approved as KISPLYX for advanced RCC in the EU.LENVIMA in combination with everolimus is approved in the U.S., EU and other regions for the treatment of adult patients with advanced RCC following one prior anti-angiogenic therapy.WELIREG is approved in the U.S., EU, Japan and other countries for the treatment of adult patients with advanced clear cell RCC following a PD-1/PD-L1 inhibitor and 1-2 VEGF-TKIs based on results from the Phase 3 LITESPARK-005 trial.About LITESPARK-012LITESPARK-012 is a randomized, open-label Phase 3 trial (ClinicalTrials.gov, NCT04736706) evaluating either the triplet therapy of KEYTRUDA plus LENVIMA plus WELIREG or MK-1308A plus LENVIMA compared to KEYTRUDA plus LENVIMA for the first-line treatment of patients with advanced clear cell RCC. The primary endpoints are PFS, as assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, and OS. Secondary endpoints are objective response rate and duration of response as assessed by BICR according to RECIST v1.1, as well as safety. The study enrolled 1,688 patients who were randomized to receive:KEYTRUDA (400 mg intravenously [IV] every six weeks [Q6W]) plus LENVIMA (20 mg orally once daily [QD]) plus WELIREG (120 mg orally QD);MK-1308A (coformulation of pembrolizumab [400 mg] and quavonlimab [25 mg] IV Q6W) plus LENVIMA (20 mg orally QD);KEYTRUDA (400 mg IV Q6W) plus LENVIMA (20 mg orally QD).All study drugs were continued until protocol-specified discontinuation criteria. KEYTRUDA and MK-1308A were administered for up to two years (approximately 18 cycles). WELIREG and LENVIMA may have been administered in combination or as a single agent until progressive disease or discontinuation.About renal cell carcinomaRenal cell carcinoma is the most common type of kidney cancer, with about nine out of 10 kidney cancer diagnoses being RCC. In 2022, there were about 435,000 new cases of kidney cancer diagnosed and approximately 156,000 deaths from the disease worldwide. Renal cell carcinoma is about twice as common in men as in women. Most cases of RCC are discovered incidentally during imaging tests for other abdominal diseases, and about 70% are a form called clear cell RCC, which tends to be more aggressive and faster spreading. Approximately 30% of patients with kidney cancer are diagnosed at an advanced stage. About Merck & Co., Inc., Rahway, NJ, USA’s research in genitourinary cancersMerck & Co., Inc., Rahway, NJ, USA is advancing research aimed at helping transform the treatment landscape and broaden options for people with genitourinary (GU) cancers, including bladder, kidney and prostate cancers. Globally, GU cancers account for an estimated 2.6 million new cancer diagnoses each year, equaling over 1 in 8 of all cancer incidences. Through a robust clinical development program with more than 50 ongoing clinical trials evaluating more than 22,000 patients around the world, Merck & Co., Inc., Rahway, NJ, USA is investigating the potential of several portfolio medicines and pipeline assets, leveraging multiple novel combination strategies, across various stages of disease, to help address unmet needs in GU cancers.About KEYTRUDA® (pembrolizumab) injection for intravenous use, 100 mgKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.Merck & Co., Inc., Rahway, NJ, USA has the industry’s largest immuno-oncology clinical research program. There are currently more than 2,800 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.About LENVIMA® (lenvatinib); available as 10 mg and 4 mg capsulesLENVIMA, discovered and developed by Eisai, is an orally available multiple receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. In syngeneic mouse tumor models, LENVIMA decreased tumor-associated macrophages, increased activated cytotoxic T cells, and demonstrated greater antitumor activity in combination with an anti-PD-1 monoclonal antibody compared to either treatment alone. LENVIMA has been approved for the indications below.Thyroid cancer– Indication as monotherapy(Approved mainly in Japan, the United States, Europe, China and Asia)Japan: Unresectable thyroid cancerThe United States: The treatment of patients with locally recurrent or metastatic, progressive, radioiodine-refractory differentiated thyroid cancer (DTC)Europe: The treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI)Hepatocellular carcinoma- Indication as monotherapy  (Approved mainly in Japan, the United States, Europe, China and Asia)Japan: Unresectable hepatocellular carcinomaThe United States: The first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)Europe: The treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy- Indication in combination with KEYTRUDA (generic name: pembrolizumab) and transarterial chemoembolization (Approved in China)Thymic carcinoma- Indication as monotherapy (Approved in Japan)Japan: Unresectable thymic carcinomaRenal cell carcinoma (In Europe other than the United Kingdom, the agent was launched under the brand name Kisplyx®)- Indication in combination with everolimus(Approved mainly in the United States, Europe and Asia)The United States: The treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior antiangiogenic therapyEurope: The treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF) targeted therapy- Indication in combination with KEYTRUDA(Approved mainly in Japan, the United States, Europe and Asia)Japan: Radically unresectable or metastatic renal cell carcinomaThe United States: The first-line treatment of adult patients with advanced renal cell carcinomaEurope: The first-line treatment of adult patients with advanced renal cell carcinomaEndometrial carcinoma- Indication in combination with KEYTRUDA(Approved mainly in Japan, the United States, Europe and Asia)Japan: Unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapyThe United States: The treatment of patients with advanced endometrial carcinoma that is pMMR or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiationEurope: The treatment of adult patients with advanced or recurrent endometrial carcinoma (EC) who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgeryAbout WELIREG® (belzutifan); available as 40 mg tablets, for oral useWELIREG, Merck & Co., Inc., Rahway, NJ, USA’s first-in-class hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor, is an orally administered small-molecule designed to reduce transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis and tumor growth. By inhibiting HIF-2α signaling, WELIREG aims to disrupt key pathways certain tumors may use to adapt to low-oxygen conditions, including those that help promote abnormal blood vessel formation and support tumor survival.WELIREG has demonstrated antitumor activity in certain von Hippel-Lindau (VHL) disease-associated tumors, renal cell carcinoma and in pheochromocytoma or paraganglioma. As part of a broader clinical program, Merck & Co., Inc., Rahway, NJ, USA continues to research WELIREG monotherapy and combination approaches for people with genitourinary, breast and gynecologic cancers across a range of treatment settings to further define where HIF-2α inhibition may provide clinical benefit and to better understand which patients are most likely to respond.About the Eisai and Merck & Co., Inc., Rahway, NJ, USA Strategic CollaborationIn March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA, known as MSD outside of the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and cocommercialization of LENVIMA. Under the agreement, the companies jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA, and HIF-2α inhibitor, WELIREG.Eisai’s focus on cancerEisai positions Oncology as one of its key strategic areas, and aims to contribute to the cure of cancers through the discovery of innovative new drugs with new targets and mechanisms of action under the Deep Human Biology Learning (DHBL) drug discovery and development organization. By utilizing biomarker data obtained from our products to elucidate the mechanisms of the incidence and root causes of cancer, as well as drug resistance, and using Eisai Group's precision chemistry technology to turn undruggable intracellular therapeutic targets into druggable ones, we will create new backbone therapeutic drugs.About EisaiEisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept [also known as our human health care (hhc) Concept], we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, our continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia, and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X (U.S. and global), LinkedIn (for U.S. and EMEA) and Facebook (global).Merck & Co., Inc., Rahway, NJ, USA’s Focus on CancerEvery day, we follow the science as we work to discover innovations that can help patients, no matter what stage of cancer they have. As a leading oncology company, we are pursuing research where scientific opportunity and medical need converge, underpinned by our diverse pipeline of more than 20 novel mechanisms. With one of the largest clinical development programs across more than 30 tumor types, we strive to advance breakthrough science that will shape the future of oncology. By addressing barriers to clinical trial participation, screening and treatment, we work with urgency to reduce disparities and help ensure patients have access to high-quality cancer care. Our unwavering commitment is what will bring us closer to our goal of bringing life to more patients with cancer. For more information, visit https://www.merck.com/research/oncology.About Merck & Co., Inc., Rahway, NJ, USAAt Merck & Co., Inc., Rahway, NJ, USA, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on  X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USAThis news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com